Optinose Announces Reporting Date for Third Quarter 2024 Financial Results

OPTN 11.05.2024

SERA-AI Powered Highlights
Date of Upcoming Event:2024-11-12
Name of Upcoming Event:Conference Call and Webcast
Full Press ReleaseSEC FilingsOur OPTN Tweets

About Gravity Analytica

Recent News

  • 01.15.2025 - Optinose Announces Preliminary Unaudited Fourth Quarter 2024 XHANCE Net Revenue of $22.4 Million
  • 12.26.2024 - Optinose Announces 1-for-15 Reverse Stock Split
  • 12.05.2024 - Piper Sandler 36th Annual Healthcare Conference

Recent Filings

  • 01.15.2025 - 8-K Current report
  • 01.15.2025 - EX-99.1 EX-99.1
  • 12.18.2024 - 4 Statement of changes in beneficial ownership of securities
Conference Call and Webcast to be held November 12, 2024, at 8:00 a.m. Eastern Time

YARDLEY, Pa.,Nov. 05, 2024(GLOBE NEWSWIRE) --Optinose(NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the third quarter 2024 and corporate updates, before market open, onTuesday, November 12, 2024.

Company to Host Conference CallMembers of the Company’s leadership team will host a conference call to discuss financial results and corporate updates. The call is scheduled to start at8:00 a.m. Eastern TimeonTuesday, November 12, 2024.

Participants may access the conference call live via webcast by visiting the Investors section of Optinose’s website athttp://ir.optinose.com/event-calendar. To participate via telephone, please register in advance atthis link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number and a personal PIN that can be used to access the call. In addition, a replay of the webcast will be available on the Company website for 60 days following the event.

AboutOptinoseOptinoseis a specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. To learn more, please visitwww.optinose.comor follow us onXandLinkedIn.

Optinose Investor ContactJonathan Neelyjonathan.neely@optinose.com267.521.0531

Primary Logo

Source: Optinose, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com